BlossomHill Therapeutics (NASDAQ:BLSM) Stock Rating Upgraded by Guggenheim

BlossomHill Therapeutics (NASDAQ:BLSM) was upgraded by equities research analysts at Guggenheim to a “strong-buy” rating in a report released on Tuesday, Zacks reports.

A number of other analysts have also recently commented on BLSM. Leerink Partners assumed coverage on BlossomHill Therapeutics in a research report on Tuesday. They set an “outperform” rating and a $36.00 target price on the stock. Lifesci Capital initiated coverage on BlossomHill Therapeutics in a research note on Tuesday. They set an “outperform” rating and a $32.00 price target on the stock. JPMorgan Chase & Co. assumed coverage on BlossomHill Therapeutics in a research report on Tuesday. They set an “overweight” rating and a $28.00 price target on the stock. Wall Street Zen upgraded BlossomHill Therapeutics to a “hold” rating in a research note on Saturday, August 15th. Finally, HC Wainwright started coverage on BlossomHill Therapeutics in a report on Tuesday. They issued a “buy” rating and a $35.00 price objective for the company. Three investment analysts have rated the stock with a Strong Buy rating and two have given a Buy rating to the company. Based on data from MarketBeat.com, BlossomHill Therapeutics has a consensus rating of “Strong Buy” and an average target price of $32.20.

BlossomHill Therapeutics Price Performance

BLSM opened at $18.99 on Tuesday. BlossomHill Therapeutics has a one year low of $15.25 and a one year high of $20.61.

Insider Buying and Selling at BlossomHill Therapeutics

In other BlossomHill Therapeutics news, Director Bihua Chen acquired 312,500 shares of the business’s stock in a transaction on Monday, August 10th. The stock was purchased at an average price of $16.00 per share, for a total transaction of $5,000,000.00. Following the completion of the transaction, the director owned 3,614,034 shares of the company’s stock, valued at $57,824,544. The trade was a 9.47% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director John P. Schmid bought 6,000 shares of BlossomHill Therapeutics stock in a transaction on Monday, August 10th. The stock was acquired at an average cost of $16.00 per share, with a total value of $96,000.00. Following the acquisition, the director owned 6,000 shares of the company’s stock, valued at $96,000. This trade represents a ? increase in their position. The SEC filing for this purchase provides additional information. In the last quarter, insiders bought 1,573,900 shares of company stock worth $25,181,900.

BlossomHill Therapeutics Company Profile

BlossomHill Therapeutics Inc is a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop small molecule medicines which address significant unmet medical needs in cancer treatment. The company’s lead clinical programs include BH-30643. BlossomHill Therapeutics Inc is headquartered in San Diego, California.